ZLAB Q3 FY26 earnings call: key takeaways

• ZLAB reported revenue of $108.2 million, which matched the $108.8 million consensus estimate (22:19)

Results vs expectations

What changed since last quarter

• The company raised its confidence in achieving year-over-year product revenue growth in 2027, citing improved performance in its China commercial business and new NRDO listings. (22:19)
• ZLAB confirmed its plan to file for a potential U.S. DLA submission in 2027, based on positive interim data from its phase 3 study. (25:49)
• The company emphasized its intention to advance Josie independently, though it remains open to partnerships that could enhance value. (31:09)

What analysts pressed on

• Whether the FDA will accept the response rate as a basis for accelerated approval for Josie. (25:24)
• How ZLAB plans to navigate the competitive landscape with Amgen's tarlatumab in the DLL-3 space. (27:53)

In their words

• We are advancing the Josie IL doublet into a global phase 3 study (13:06)
• We believe these results are unprecedented in first-line small cell lung cancer Rafael (15:56)
• Our ambition extends well beyond OC (13:06)
• We expect a return to year-over-year product revenue growth in 2027 Yayin (22:19)